JNJ Stock Recent News Johnson & Johnson (JNJ) 108.16 11/14/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Johnson & Johnson (JNJ) 108.16 $JNJ

Final Glance: Pharmaceuticals companies
AP - 1 hr 13 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.16 (-0.91), BAX: 71.75 (-0.33), PFE: 30.34 (-0.08), BMY: 57.95 (+0.15)

Final Glance: Medical Devices companies
AP - 1 hr 13 mins ago
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
ZMH: 110.12 (-0.49), JNJ: 108.16 (-0.91), MDT: 68.95 (-0.43), BAX: 71.75 (-0.33)

Geron Collaborates with J&J for Imetelstat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 17 mins ago
Geron Corporation (GERN), a clinical-stage biopharmaceutical company, announced that it has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc., a unit of Johnson & Johnson (JNJ).
BIIB: 305.43 (-12.55), JNJ: 108.16 (-0.91), GERN: 2.76 (+0.45), AFFX: 9.71 (+0.02)

Halliburton and Geron are big market movers
AP - 2 hrs 47 mins ago
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
SINA: 39.80 (-2.05), AMZN: 327.82 (+11.34), JNJ: 108.16 (-0.91), HTZ: 21.69 (-1.04), GERN: 2.76 (+0.45), HAL: 55.08 (+1.29), JWN: 74.17 (+0.92), NOK: 7.86 (-0.40), BHI: 59.89 (+1.14)

Geron's Short Squeeze Is Here
Vahan Avetisyan - Seeking Alpha - Fri Nov 14, 2:40PM CST
Geron' s 2014 D eal to the Rescue Geron (NASDAQ: GERN ) surprised Thursday after-hours when it announced news that it entered into an exclusive worldwide license and collaboration agreement to develop its blood disorder drug imetelstat with...
JNJ: 108.16 (-0.91), GERN: 2.76 (+0.45)

Mallinckrodt Shares Down on Setback for Generic Concerta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 2:39PM CST
Mallinckrodt (MNK) received a setback when the FDA informed the company that its methylphenidate hydrochloride extended-release tablets, USP (CII) might not be therapeutically equivalent to Johnson & Johnson's (JNJ) Concerta.
MNK: 88.11 (+1.15), BIIB: 305.43 (-12.55), JNJ: 108.16 (-0.91), ACT: 243.77 (+2.14)

Stock Market Today: Stocks Mixed as Retail Sales Climb, House OKs Keystone Pipeline
at The Street - Fri Nov 14, 2:36PM CST
U.S. stocks fluctuate on Friday, caught between better-than-expected retail sales and more worries of eurozone deflation.
SINA: 39.80 (-2.05), JNJ: 108.16 (-0.91), HTZ: 21.69 (-1.04), VA: 30.00 (+30.00), GERN: 2.76 (+0.45), JWN: 74.17 (+0.92)

Midday Glance: Pharmaceuticals companies
AP - Fri Nov 14, 12:17PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 1 p.m.:
JNJ: 108.16 (-0.91), BAX: 71.75 (-0.33), PFE: 30.34 (-0.08), BMY: 57.95 (+0.15)

Midday Glance: Medical Devices companies
AP - Fri Nov 14, 12:17PM CST
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
ZMH: 110.12 (-0.49), JNJ: 108.16 (-0.91), MDT: 68.95 (-0.43), BAX: 71.75 (-0.33)

Early Glance: Medical Devices companies
AP - Fri Nov 14, 9:47AM CST
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
ZMH: 110.12 (-0.49), JNJ: 108.16 (-0.91), MDT: 68.95 (-0.43), BAX: 71.75 (-0.33)

Early Glance: Pharmaceuticals companies
AP - Fri Nov 14, 9:47AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 10 a.m.:
JNJ: 108.16 (-0.91), BAX: 71.75 (-0.33), PFE: 30.34 (-0.08), BMY: 57.95 (+0.15)

Setting Up A Portfolio That Millennials Can Relate To
FinancialDave - at Seeking Alpha - Fri Nov 14, 9:05AM CST

JNJ: 108.16 (-0.91), VTV: 83.79 (+0.02), SPY: 204.24 (+0.05)

Nicholas Valeriani Appointed To Edwards Lifesciences' Board Of Directors
PR Newswire - Fri Nov 14, 8:00AM CST
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that Nicholas J. Valeriani has been appointed to its board of directors and will also serve as a member of its Compensation and Governance Committee. Since 2012, Valeriani, 58, has been the Chief Executive Officer of the Gary and Mary West Health Institute, an independent, nonprofit medical research organization that works to create new, more effective ways of delivering care at lower costs. Prior to joining West Health, Valeriani spent 34 years at Johnson & Johnson and served as a member of its executive committee.
JNJ: 108.16 (-0.91), EW: 124.50 (-0.05)

Global Clinical Chemistry Analyzer (Basic Metabolic, Electrolyte, Liver, Lipid, Renal, Thyroid Function, Specialty Chemicals) Market - Forecast to 2019
M2 - Fri Nov 14, 5:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/jzzrg4/clinical) has announced the addition of the "Clinical Chemistry Analyzer Market by Product, Test Type, End User - Global Forecast to 2019" report to their offering. Clinical chemistry analyzers are the most widely used equipments in clinical laboratories. A large quantity of reagents and other consumables are required for various types of tests. Basic metabolic panel tests are the largest test segment for the clinical chemistry analyzer market in 2014, whereas the lipid profile test segment is expected to grow at the highest CAGR between 2014 and 2019. Growth in the basic metabolic panel tests, aided by growing trends of preventive medicine and increasing incidence in lifestyle disease will drive the growth of the market. This report segments the global clinical chemistry analyzer market into analyzers, reagents and other products. The market is further sub segmented into Small (400-800 Test/H), Medium (800-1,200 Tests/H), Large (1,200-2,000 Tests/H), Very large (2,000 Tests/H). The clinical chemistry reagents market is sub segmented into calibrators, controls, standards and other reagents. The major players in the clinical chemistry analyzer market include Roche Diagnostics (Switzerland), Beckman Coulter (U.S.) Abbott Diagnostics (U.S.) Siemens AG (Germany), Ortho-Clinical Diagnostics (U.S.), Thermo Fisher Scientific (U.S.) Randox Laboratories Ltd. (U.K.), ElitechGroup (France), Mindray (China), Horiba (Japan). Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Clinical Chemistry Analyzers Market, By Product 8 Clinical Chemistry Analyzers Market, By Test 9 Clinical Chemistry Analyzers Market, By End Users 10 Geographic Analysis 11 Competitive Landscape 12 Company Profiles 13 Appendix Companies Mentioned: - Abbott Laboratories - Danaher Corporation - Elitech - F. Hoffmann-La Roche - Horiba - Johnson & Johnson - Mindray Medical International Limited - Randox Laboratories - Siemens - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/jzzrg4/clinical
JNJ: 108.16 (-0.91), ABT: 43.81 (-0.78), DHR: 82.23 (-0.17), MR: 31.06 (-0.16)

The Post AASLD Annual Meeting Hepatitis C Landscape
Leonard Yaffe - at Seeking Alpha - Fri Nov 14, 5:15AM CST

JNJ: 108.16 (-0.91), GILD: 102.06 (-2.14), MRK: 59.07 (-0.47), ABBV: 64.00 (+0.37)

Is Johnson & Johnson A Stock Worth Having In The Portfolio Right Now?
Abba's Aces - at Seeking Alpha - Fri Nov 14, 1:36AM CST

JNJ: 108.16 (-0.91), PFE: 30.34 (-0.08), ABBV: 64.00 (+0.37)

ADHD drug hits FDA trouble
at Investor's Business Daily - Thu Nov 13, 5:37PM CST
Drugmaker Mallinckrodt (MNK) said that the FDA is no longer recognizing its generic ADHD drug, methylphenidate ER, as an equivalent to Johnson & Johnson's (JNJ) Concerta and is reclassifying the treatment as "therapeutically inequivalent."...
MNK: 88.11 (+1.15), JNJ: 108.16 (-0.91)

Geron wins deal to develop blood disorder drug, could get $935M
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 4:55PM CST

JNJ: 108.16 (-0.91), GERN: 2.76 (+0.45)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 110

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 394

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 570

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Anthropic Bears Get New Tools, But Daily Risk Bites

Updated Category News Views 64

A $81.3 Billion Offering Invites Fast Money Anthropic arrived in public markets with the sort of numbers that make traders reach for both a calculator and a helmet. The company priced 980 million Class A shares at $83 on November 18, 2026, raising roughly $81.3 billion, then opened at $111.50 when it began Nasdaq trading on November 19. That is a monster debut by any...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 140

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 43

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 69

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 459

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading

Top 5 Most Recently Viewed Articles

3Srobotics Breaks Ground with North American Debut

Updated Category News Views 204

3Srobotics Steps Into the Big League The sweltering buzz of FABTECH 2026 in Las Vegas signals more than just another industry tradeshow; it's the stage upon which 3Srobotics made its North American debut. In a span shorter than it takes most companies to get serious about their business cards, 3Srobotics has already nailed three funding rounds, snagging tens of millions...

Continue Reading
Uganda Plans Major Spending Cuts and Reduced Borrowing for 2025

Updated Category News Views 912

Uganda's government announced a hefty shift in its fiscal playbook back in 2024, aiming to cut spending by over 20% and slash domestic borrowing by more than half for the upcoming 2025/26 fiscal year. This wasn’t just some routine budgetary tweak; it was a necessary maneuver amidst growing alarm about the nation's spiraling public debt. You know these moves grab...

Continue Reading
Vivos Therapeutics to Share Q1 2025 Results and Updates Soon

Updated Category News Views 257

Vivos Therapeutics Prepares for Q1 2025 Financial Disclosure Vivos Therapeutics, Inc. (NASDAQ: VVOS), a pioneering company in the medical devices sector, is gearing up to release its financial results for the first quarter of 2025. This announcement is anticipated to take place following the market's closure on a Thursday in May 2025. The management team is set to hold a...

Continue Reading
Join XBP Global for the Annual Turkey Trot This Thanksgiving

Updated Category News Views 217

XBP Global Welcomes You to the 11th Annual Turkey Trot XBP Global Holdings, Inc. (NASDAQ: XBP) is thrilled to invite the community to the 11th Annual Palisades Turkey Trot, a cherished tradition returning this Thanksgiving morning. Held at Palisades Green, this year's event promises excitement with new 5K and 10K courses that enhance the festive atmosphere of the...

Continue Reading
Market Reaction to CEO Departure and Boot Barn's Strong Quarter

Updated Category News Views 317

Boot Barn Stock Forecast Amid CEO Transition and Solid Performance In the latest developments regarding Boot Barn (NYSE: BOOT), analysts at Craig-Hallum have made notable adjustments to their stock price outlook. The price target has been revised to $160 from a previous $162, maintaining a Hold rating. The adjustments come in light of the company's impressive performance...

Continue Reading